Tag: Fcrn inhibitors

Many autoimmune diseases and certain cancers are characterized by abnormally high levels of immunoglobulin G (IgG) and pathogenic autoantibodies. Understanding **what medications can lower IgG levels** is crucial for targeted therapeutic interventions in these conditions, and a variety of pharmacological approaches exist to achieve this goal.

In recent years, the treatment landscape for myasthenia gravis has been transformed by a new generation of targeted therapies. A particularly significant development is the April 2025 FDA approval of IMAAVY™ (nipocalimab), which represents a **new drug for myasthenia** for adults and adolescents with generalized myasthenia gravis (gMG).